A Phase 3 Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Administration of Fovista (Anti PDGF-B Pegylated Aptamer) Administered in Combination With Either Avastin or EyleaCompared to Avastin or Eylea Monotherapy in Subjects With Subfoveal Neovascular Age-related Macular Degeneration

Trial Profile

A Phase 3 Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Administration of Fovista (Anti PDGF-B Pegylated Aptamer) Administered in Combination With Either Avastin or EyleaCompared to Avastin or Eylea Monotherapy in Subjects With Subfoveal Neovascular Age-related Macular Degeneration

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs Pegpleranib (Primary) ; Aflibercept; Bevacizumab
  • Indications Wet age-related macular degeneration
  • Focus Registrational; Therapeutic Use
  • Sponsors OphthoTech Corporation
  • Most Recent Events

    • 14 Aug 2017 Results published in an Ophthotech Corporation media release.
    • 14 Aug 2017 Status changed from active, no longer recruiting to completed, According to an OphthoTech Corporation media release.
    • 14 Aug 2017 Primary endpoint (Mean change in visual acuity from baseline at the Month 12 visit.) has not been met, according to an Ophthotech Corporation media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top